Mercury's 'missing' meteorites may have finally been found on Earth
Most meteorites that have reached Earth come from the asteroid belt between Mars and Jupiter. But we have 1,000 or so meteorites that come from the Moon and Mars. This is probably a result of asteroids hitting their surfaces and ejecting material towards our planet.
It should also be physically possible for such debris to reach the Earth from Mercury, another nearby rocky body. But so far, none have been confirmed to come from there — presenting a longstanding mystery.
A new study my colleagues and I conducted has discovered two meteorites that could have a Mercurian origin. If confirmed, they would offer a rare window into Mercury's formation and evolution, potentially reshaping our understanding of the planet nearest the Sun.
Because Mercury is so close to the Sun, any space mission to retrieve a sample from there would be complex and costly. A naturally delivered fragment, therefore, may be the only practical way to study its surface directly — making such a discovery scientifically invaluable.
Observations from NASA's Messenger mission have inferred the surface composition of Mercury. This suggests the presence of minerals known as such as sodium-rich plagioclase (such as albite), iron-poor pyroxene (for example enstatite), iron-poor olivine (such as forsterite) and sulfide minerals such as oldhamite.
The meteorite Northwest Africa (NWA) 7325 was initially proposed as a possible fragment of Mercury. However, its mineralogy includes chromium-rich pyroxene containing approximately 1% iron. This poorly matches Mercury's estimated surface composition. As a result of this, and other factors, this link has been challenged.
Related: Mercury may have a 'potentially habitable' region below its surface, salty glaciers suggest
Aubrite meteorites have also been proposed as potential Mercurian fragments. Recent modeling of their formation suggests an origin from a large planetary body approximately 5,000km in diameter (similar to Mercury), potentially supporting this hypothesis.
Although aubrites do not exhibit chemical or spectral (the study of how light is broken up by wavelength) similarities with Mercury's surface, it has been hypothesized that they may derive from the planet's shallow mantle (the layer beneath the surface). Despite ongoing research, the existence of a definitive meteorite from Mercury remains unproven.
Our latest study investigated the properties of two unusual meteorites, Ksar Ghilane 022 and Northwest Africa 15915. We found that the two samples appear to be related, probably originating from the same parent body. Their mineralogy and surface composition also exhibit intriguing similarities to Mercury's crust. So this has prompted us to speculate about a possible Mercurian origin.
Both meteorites contain olivine and pyroxene, minor albitic plagioclase and oldhamite. Such features are consistent with predictions for Mercury's surface composition. Additionally, their oxygen compositions match those of aubrites. These shared characteristics make the samples compelling candidates for being Mercurian material.
However, notable differences exist. Both meteorites contain only trace amounts of plagioclase, in contrast to Mercury's surface, which is estimated to contain over 37%. Furthermore, our study suggests that the age of the samples is about 4,528 million years old. This is significantly older than Mercury's oldest recognised surface units, which are predicted (based on crater counting) to be approximately 4,000 million years.
If these meteorites do originate from Mercury, they may represent early material that is no longer preserved in the planet's current surface geology.
To link any meteorite to a specific asteroid type, moon or planet is extremely challenging. For example, laboratory analysis of Apollo samples allowed meteorites found in desert collection expeditions to be matched with the lunar materials. Martian meteorites have been identified through similarities between the composition of gases trapped in the meteorites with measurements of the martian atmosphere by spacecraft.
Until we visit Mercury and bring back material, it will be extremely difficult to assess a meteorite-planet link.
The BepiColombo space mission, by the European and Japanese space agencies, is now in orbit around Mercury and is about to send back high-resolution data. This may help us determine the ultimate origin body for Ksar Ghilane 022 and Northwest Africa 15915.
If meteorites from Mercury were discovered, they could help resolve a variety of long-standing scientific questions. For example, they could reveal the age and evolution of Mercury's crust, its mineralogical and geochemical composition and the nature of its gases.
RELATED STORIES
—Mercury is weird because of a 'hit-and-run' incident in its youth
—See Mercury's frigid north pole in extraordinary new images from the BepiColombo spacecraft
—9-mile-thick layer of solid diamonds may lurk beneath Mercury's surface, study hints
The origin of these samples is likely to remain a subject of continuing debate within the scientific community. Several presentations have already been scheduled for the upcoming Meteoritical Society Meeting 2025 in Australia. We look forward to future discussions that will further explore and refine our understanding of their potential origin.
For now, all we can do is make educated guesses. What do you think?
This edited article is republished from The Conversation under a Creative Commons license. Read the original article.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
an hour ago
- Gizmodo
The Movie Everyone Thought Would Be ‘Dune Messiah' Is Now Officially ‘Dune: Part 3'
Though there's still no official release date, Dune fans have long assumed director Denis Villeneuve is readying production on the third film in the sci-fi series. Some casting news a few weeks back helped strengthen that notion—and now we have a title locked in. Surprisingly, it's not Dune Messiah, in keeping with Frank Herbert's source-material novel. It's… drum roll… Dune: Part Three. According to Variety, Dune: Part Three is still expected to release in December 2026, the slot previously reserved for an 'event movie' from the director by Warner Bros. At the time, the given date of December 18, 2026, conflicted with an unnamed Star Wars project that has since been removed—but is now the release date for a little movie called Avengers: Doomsday. So it's anyone's guess if Dune: Part Three will remain in place. (Lest we forget, Dune: Part Two shifted release dates a few times and was still a massive hit.) The Variety piece also notes that while some sequences in Dune: Part Three will be filmed using IMAX cameras, the whole film will not be shot in the format, as had been suggested by IMAX CEO Paul Gelfond. That means Christopher Nolan's currently in production The Odyssey will remain the only film entirely shot using IMAX cameras, at least until the next ambitious filmmaker takes the plunge. (Perhaps it'll still be Villeneuve, once he shifts gears to start work on his James Bond movie?) The trade notes that Dune: Part Three is expected to begin filming 'imminently,' with Timothée Chalamet and Zendaya returning to star. Jason Momoa, absent from Part Two, is also back in the cast. Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what's next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.
Gizmodo
2 hours ago
- Gizmodo
The Next Big Cancer Treatment Could Be Herpes
Scientists are developing all sorts of potential new treatments to tackle the most difficult cancer cases—including some that will make you thankful for the existence of herpes and other viruses. Clinical trial data out today shows that a modified version of the herpes simplex virus 1 (HSV-1) can help keep late-stage skin cancer at bay. Researchers at the University of Southern California and others conducted the study, a Phase I/II trial of people with advanced, treatment-resistant melanoma. About a third of patients given the modified virus, in combination with immunotherapy, saw their tumors substantially shrink, while some even experienced a complete regression of their cancer. A larger, definitive trial of the experimental therapy, code-named RP1, is already underway, and the Food and Drug Administration will decide on an approval later this month. Scientists have been intrigued about the promise of cancer-fighting, or oncolytic, viruses for over a century, according to study author Gino In, a medical oncologist at USC's Keck School of Medicine. But it's only recently that this potential has started to look within reach. 'Most progress has been made just in the last few decades, thanks to advances and progression in gene editing technologies, which have allowed researchers to specifically design oncolytic viruses that are more effective and safer,' In told Gizmodo. HSV-1, the primary cause of cold sores, has emerged as a particularly promising candidate for cancer treatment. HSV-1 is a relatively large virus, meaning scientists can replace or add new genes without too much trouble. And though it does use our cells to replicate, like any virus, it doesn't insert its DNA into a cell's genome directly, eliminating the risk of certain mutations (an important consideration for safety). A typical HSV-1 infection also isn't life-threatening and can be treated with antiviral medications if needed, further limiting its potential danger. These properties have allowed scientists to create strains of the virus that can selectively target cancer cells. The first herpes-based cancer therapy (T-VEC) was approved in the U.S. in 2015 for some cases of metastatic melanoma. But researchers like In are especially excited by the new generation of these treatments. A Cancer-Fighting Version of Herpes Shows Promise in Early Human Trial RP1 is the brainchild of biotech company Replimune, and it's one of several cancer-fighting viruses that the company is currently developing. Compared to the typical HSV-1 virus, RP1 has been weakened, meaning it shouldn't be able to cause severe infections. It's also been modified to not only target cancer cells, but to also boost the immune system's natural tumor-killing ability. 'These changes make RP1 both safer and better at killing cancer cells than natural HSV-1,' In explained. And while RP1 might be a viable treatment on its own, Replimune is also testing whether it can be even more effective when paired with other existing immunotherapies. This latest study involved 140 patients from the company's IGNYTE trial of RP1 conducted across several sites, including at USC. The participants had late-stage melanoma that was unresponsive to earlier immunotherapy treatment. They received both RP1 and nivolumab, an immunotherapy drug commonly used for melanoma, every two weeks for up to four months. If patients responded to the initial treatment, they continued taking nivolumab alone for up to two years. By the study's end, a third of patients saw their tumors decrease in size by at least 30%, the researchers found, and almost one in every six patients had their tumors disappear entirely. Importantly, this shrinkage was seen in tumors directly injected with RP1 as well as uninjected tumors throughout the body—indicating its immune-boosting potential worked as hoped. The combination therapy also appeared to be safe, with most patients only experiencing minor adverse events like fatigue or other flu-like symptoms. The findings were presented earlier this year at the annual meeting of the American Society of Clinical Oncology and are set to be published soon in the Journal of Clinical Oncology. 'This study provides an important new approach for patients with immunotherapy-refractory melanoma; this is very important since about half of all melanoma patients do not benefit from immunotherapy,' said In. 'So it provides a new type of treatment, one that is both effective and well tolerated.' Experimental Therapy Fights Brain Cancer with Modified Herpes Virus Early trials are primarily intended to vet an experimental treatment's safety and optimal dosing, not its effectiveness. But given the general outlook of these normally untreatable cases, there's certainly reason to be optimistic here. Last year, Replimune launched a Phase III trial that will test RP1 combined with nivolumab in around 400 people with treatment-resistant melanoma. But even before this study concludes, RP1 could become available to the public. In January, the FDA agreed to consider the combination therapy for accelerated approval, a process that allows a novel treatment to be tentatively approved with less direct evidence of its effectiveness (further trial data is still required to secure a full approval). The FDA's decision on RP1 is scheduled for July 22. In and the USC team will continue to study their data to better understand how RP1 works. But they expect RP1 to become a new option for these resistant melanoma cases, and In notes that RP1 is also being tested for other kinds of cancer. If things keep going right, virus-based therapies like RP1 could soon become the next frontier of cancer treatment.
Washington Post
2 hours ago
- Washington Post
Oprah's book club pick ‘Culpability' taps into our AI anxiety
Artificial intelligence is accelerating faster than a Tesla toward an oak tree. Every day brings a fresh story — possibly written by AI — about the wonders of a world remastered by autonomous billionaires and their silicon golems. Perplexity, indeed. Bruce Holsinger's novel 'Culpability,' about a deadly crash involving a self-driving vehicle, was originally slated for October, but Oprah just named it her July book club pick, so you can already find it parked in your local bookstore. Whatever the reason, that was a fortuitous rescheduling. When it comes to writing about artificial intelligence, three months is the distance between rubbing sticks together and splitting an atom.
